These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36378830)

  • 1. Mechanism-Based Pharmacokinetic Modeling of Absorption and Disposition of a Deferoxamine-Based Nanochelator in Rats.
    Jones G; Zeng L; Kim J
    Mol Pharm; 2023 Jan; 20(1):481-490. PubMed ID: 36378830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
    Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
    Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Allometric Scaling to Nanochelator Pharmacokinetics.
    Jones G; Zeng L; Kim J
    ACS Omega; 2023 Aug; 8(30):27256-27263. PubMed ID: 37546686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactive Oxygen Species-Triggered Dissociation of a Polyrotaxane-Based Nanochelator for Enhanced Clearance of Systemic and Hepatic Iron.
    Liu Z; Simchick GA; Qiao J; Ashcraft MM; Cui S; Nagy T; Zhao Q; Xiong MP
    ACS Nano; 2021 Jan; 15(1):419-433. PubMed ID: 33378155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBED: A potential alternative to deferoxamine for iron-chelating therapy.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 1998 Feb; 91(4):1446-52. PubMed ID: 9454776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal clearable nanochelators for iron overload therapy.
    Kang H; Han M; Xue J; Baek Y; Chang J; Hu S; Nam H; Jo MJ; El Fakhri G; Hutchens MP; Choi HS; Kim J
    Nat Commun; 2019 Nov; 10(1):5134. PubMed ID: 31723130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.
    Kalanaky S; Hafizi M; Safari S; Mousavizadeh K; Kabiri M; Farsinejad A; Fakharzadeh S; Nazaran MH
    Int J Hematol; 2016 Mar; 103(3):274-82. PubMed ID: 26830968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
    Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
    Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of Brainstem Hemorrhage.
    Guo X; Qi X; Li H; Duan Z; Wei Y; Zhang F; Tian M; Ma L; You C
    World Neurosurg; 2019 Aug; 128():e895-e904. PubMed ID: 31082547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
    Liu Z; Qiao J; Nagy T; Xiong MP
    J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
    Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators.
    Park SH; Kim RS; Stiles WR; Jo M; Zeng L; Rho S; Baek Y; Kim J; Kim MS; Kang H; Choi HS
    Adv Sci (Weinh); 2022 May; 9(15):e2200872. PubMed ID: 35343104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier.
    Tyagi P; Kumar A; Gupta D; Singh H
    AAPS PharmSciTech; 2017 Jan; 18(1):156-165. PubMed ID: 26912356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
    Farr AC; Xiong MP
    Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy.
    Xu L; Guan R; Yu B; Li Y; Liu H; Jiang Y
    Int J Pharm; 2022 Sep; 625():122136. PubMed ID: 36029994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.